Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025

Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025 This activity is designed to educate hematologists, oncologists, and other clinicians on new developments in the diagnosis and treatment of all blood cancers. Through disease specific lectures, highlighting the most clinically relevant data presented at the ASH Annual Meeting, attendees will be able to identify and describe the emerging treatments available and to utilize these treatments available in their professional practice.

The American Society of Hematology’s annual meeting in December is the venue at which cutting edge therapeutic advances are presented publicly for the first time. Unfortunately, only a small fraction of practitioners can attend this meeting. It is therefore of vital importance for practitioners and, in turn, their patients to have access to emerging data in a timely fashion. At this one-day activity, attendees will receive relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, and CAR-T therapies.

Who Should Attend

This course is targeted to Oncology and Hematology Physicians and Trainees, Primary Care Physicians, Nurses, Physician Assistants, and Nurse Practitioners.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe an overview and highlight the recent medical advances present at the Annual Meeting of the American Society of Hematologists (ASH) which will help physicians achieve better patient outcomes.
• Recognize appropriate management and treatment options for hematologic malignancies.
• Utilize these approaches in routine clinical practice.
• Review new therapies and approaches in non-malignant hematology.